1540 BROADWAY, NEW YORK, NY
Reports Second Quarter 2026 Financial Results
Eli Lilly Acquires Ajax Therapeutics; Schrödinger Receives $57 Million
Approval of 2026 Plan Amendment by Schrödinger, Inc. Stockholders
Separation Agreement with Mannix Aklian Following Departure as CCO
Material disclosure
Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Therese Abrams Appointed Principal Accounting Officer at Schrödinger, Inc.
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
S-1MEF
Correspondence
Submission Upload